ATNM | tickerfilter.com

Fundamental analysis

Profitability 8%

Dept financing 14%

Liquidity 50%

Performance 0%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-6.20%

1 Month

8.04%

3 Months

-5.47%

6 Months

-23.42%

1 Year

-86.53%

2 Year

-86.83%

Key data

Stock price

$1.21

P/E Ratio

0.00

DAY RANGE

$1.20 - $1.30

EPS

-$1.39

52 WEEK RANGE

$1.03 - $10.24

52 WEEK CHANGE

-$86.54

MARKET CAP

58.414 M

YIELD

N/A

SHARES OUTSTANDING

29.783 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

04-15-2025

BETA

3.22

PUBLIC FLOAT

AVERAGE 10 VOLUME

$426,368

AVERAGE 30 VOLUME

$1,320,269

Company detail

CEO: Sandesh Seth
Region: US
Website: actiniumpharma.com
Employees: 30
IPO year: 2011

Issue type: Common Stock
Market: NYSE American
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Actinium Pharmaceuticals, Inc. focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning. The company also offers clinical and preclinical development programs that utilize multiple isotopes.

ATNM - Actinium Pharmaceuticals, Inc.